Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
United European Gastroenterology Journal · 2024-07 · 12 (6) · 793-801
DOI: 10.1002/ueg2.12584 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 22.05.2024. Verfasst von Julian Panés und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Colitis, Ulcerative, Pyrroles. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background and Aims Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report an integrated summary of tofacitinib safety from the completed global UC clinical program (9.2 years maximum tofacitinib exposure).
Methods
This analysis included patients receiving tofacitinib 5 or 10 mg twice daily (b.i.d.) from completed phase 2/3 placebo‐controlled studies, an open‐label, long‐term extension study and a randomized phase 3b/4 study. Proportions and incidence rates (IRs; unique patients with events/100 patient‐years [PY] of exposure) were evaluated for deaths and adverse events (AEs) of special interest (AESI).
Results
Overall, 1157 patients received ≥1 dose of tofacitinib 5 or 10 mg b.i.d.; 938 (81.1%) were in the predominant dose tofacitinib 10 mg b.i.d. group; 552 (47.7%) received tofacitinib for ≥2 years; total exposure: 3202.0 PY; 994 (85.9%) experienced AEs; 254 (22.0%) experienced serious AEs. Median treatment duration: 1.7 (range 0.0–9.2) years. IRs (95% CI) for combined tofacitinib doses: deaths 0.24 (0.10–0.48); serious infections (SIs) 1.80 (1.37–2.32); herpes zoster (HZ; non‐serious and serious) 3.24 (2.63–3.94); serious HZ 0.24 (0.10–0.48); opportunistic infections 0.96 (0.65–1.36); malignancies (excluding non‐melanoma skin cancer [NMSC]) 0.88 (0.59–1.26); NMSC 0.71 (0.45–1.07); major adverse cardiovascular events 0.27 (0.12–0.52); deep vein thrombosis 0.06 (0.01–0.22); pulmonary embolism 0.18 (0.07–0.40); and gastrointestinal perforations 0.09 (0.02–0.27).
Conclusions
Except for HZ and SIs, IRs for AESI were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
- Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
- Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong.
- Pfizer Inc, Collegeville, Pennsylvania, USA.
- Pfizer Inc, Groton, Connecticut, USA.
ORCID-Profile: Julian Panés, Siew C Ng, Xiang Guo, Séverine Vermeire
Förderung
- Pfizer
Zitieren
APA
Panés, J., D'Haens, G. R., Sands, B. E., Ng, S. C., Lawendy, N., Kulisek, N., Guo, X., Wu, J., Vranic, I., Panaccione, R., & Vermeire, S. (2024). Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterology Journal, 12(6), 793-801. https://doi.org/10.1002/ueg2.12584
Vancouver
Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, et al. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterology Journal. 2024;12(6):793-801. doi:10.1002/ueg2.12584
BibTeX
@article{Pans2024,
author = {Panés, Julian and D'Haens, Geert R and Sands, Bruce E and Ng, Siew C and Lawendy, Nervin and Kulisek, Nicole and Guo, Xiang and Wu, Joseph and Vranic, Ivana and Panaccione, Remo and Vermeire, Séverine},
title = {Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure},
journal = {United European Gastroenterology Journal},
year = {2024},
volume = {12},
number = {6},
pages = {793--801},
doi = {10.1002/ueg2.12584}
}
EUVIMED